Plenary Sessions
Monday, May 18, 2015
9:00 AM - 10:30 AM
Room: Grand Ballroom, Salon A-F (Level 5)
FIRST PLENARY SESSION: TAKING STOCK OF THE LEARNING HEALTH CARE SYSTEM: WHAT HAVE WE ACHIEVED AND WHY DOES IT MATTER?
Nearly a decade ago, leaders envisioned a pathway to a learning health care system, where research is closely integrated and rapidly translated into practice by making use of electronic data that can track patients across health care providers and time. Since then, there has been substantial public and private investment to make this vision a reality. This session critically examines how far we have come and what the implications are for comparative effectiveness researchers, payers, patients, and the life sciences industry.
Moderator: Penny Mohr, MA bio
Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Toward a True Learning Health System: How Can We Build Both the Will and the Skill?
Speaker: Sarah Greene, MPH bio
Associate Director, CER Methods and Infrastructure, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Health Care Transformation and the Learning Health System: Where Are We and What’s Next?
Speaker: Lewis G. Sandy, MD, FACP bio
Senior Vice President, Clinical Advancement, UnitedHealth Group, Minneapolis, MN, USA
The Learning Health System: An Optimist's Perspective
Speaker: Sachin H. Jain, MD, MBA bio
Chief Medical Officer, CareMore/Anthem and Lecturer in Health Care Policy, Harvard Medical School, Cerritos, CA, USA
Tuesday, May 19, 2015
9:00 AM - 10:30 AM
Room: Grand Ballroom, Salon A-F (Level 5)
SECOND PLENARY SESSION: COST-EFFECTIVENESS AND CLINICAL PRACTICE GUIDELINES: HAVE WE REACHED A TIPPING POINT?
In recent years, both oncology and cardiology professional organizations have embraced the explicit consideration of cost-effectiveness and the value of treatments in developing and updating clinical practice guidelines and clinical pathways. This is a new development in the U.S. health care system, and one which is complicated by the pluralistic nature of the system. The impact that it could ultimately have on medical practice is not clear neither in terms of access to care and providers nor in terms of incentives for innovation. This session will explore the implications of this change for the range of stakeholders involved, including U.S. private insurers, clinicians, patients, and federal government programs.
Moderator: Lou Garrison, PhD bio
Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Considering Cost-Effectiveness In Cardiology Clinical Guidelines: Progress and Prospects
Speaker: Mark A. Hlatky, MD bio
Professor of Health Research and Policy and Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA, USA
Challenges in Measuring Cost and Value in Oncology: Making It Personal
Speaker: Peter P. Yu, MD, FACP, FASCO bio
Director of Cancer Research, Palo Alto Medical Foundation, Sunnyvale, CA and President, American Society of Clinical Oncology (ASCO), Alexandria, VA, USA
Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
Speaker: Michael Drummond, MCom, DPhil bio
Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Wednesday, May 20, 2015
9:45 AM - 11:00 AM
Room: Grand Ballroom, Salon A-F (Level 5)
THIRD PLENARY SESSION: BIG DATA, BIG SYSTEMS, AND BETTER EVIDENCE: WHAT PROGRESS?
What could the growing interest in big data mean for health delivery systems and patients? This session will explore the challenges for incorporating big data into health system decisions and processes. A number of related questions will be explored. Can big data be used to improve evidence and clinical decision making? Is there a need for new analytical approaches? How will these developments affect patients?
Moderator: Adrian Towse, MA, MPhil bio
Director, Office of Health Economics, London, UK
Speaker: Ari Caroline bio
Chief Analytics Officer, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Speaker: Ami Ehlenberger bio
Director of Client Solutions, IBM Watson Group, Philadelphia, PA, USA
Speaker: Paul Wallace, MD bio
Chief Medical Officer & Senior Vice President, Clinical Translation, Optum Labs and Chair, Board of Directors, AcademyHealth, Cambridge, MA, USA
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.